References
- Jeppesen PB, Mortensen PB. Intestinal failure defined by measurements of intestinal energy and wet weight absorption. Gut 46(5), 701–706 (2000).
- Jeppesen PB, Langholz E, Mortensen PB. Quality of life in patients receiving home parenteral nutrition. Gut 44(6), 844–852 (1999).
- Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 124(4), 1111–1134 (2003).
- Spiller RC, Trotman IF, Adrian TE, Bloom SR, Misiewicz JJ, Silk DB. Further characterisation of the ‘ileal brake’ reflex in man–effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY. Gut 29(8), 1042–1051 (1988).
- Nightingale JM, Kamm MA, van der Sijp JR et al. Disturbed gastric emptying in the short bowel syndrome. Evidence for a ‘colonic brake’. Gut 34(9), 1171–1176 (1993).
- Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, Mortensen PB. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 45(4), 559–563 (1999).
- Drucker DJ, Erlich P, Asa SL et al. Induction of intestinal epithelial proliferation by glucagon- like peptide 2. Proc. Natl Acad. Sci. USA 93(15), 7911–7916 (1996).
- Wøjdemann M, Wettergren A, Hartmann B, Holst JJ. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand. J. Gastroenterol. 33(8), 828–832 (1998).
- Wøjdemann M, Wettergren A, Hartmann B, Hilsted L, Holst JJ. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J. Clin. Endocrinol. Metab. 84(7), 2513–2517 (1999).
- Bremholm L, Hornum M, Andersen UB, Hartmann B, Holst JJ, Jeppesen PB. The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul. Pept. 168(1–3), 32–38 (2011).
- Cani PD, Possemiers S, Van de Wiele T et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58(8), 1091–1103 (2009).
- Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am. J. Physiol. 272(6 Pt 1), E1050–E1058 (1997).
- Jeppesen PB, Hartmann B, Thulesen J et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120(4), 806–815 (2001).
- Jeppesen PB, Lund P, Gottschalck IB et al. Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol. Res. Pract. 2009, 616054 (2009).
- Jeppesen PB, Lund P, Gottschalck IB et al. Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life. Gastroenterol. Res. Pract. 2009, 425759 (2009).
- Jeppesen PB, Sanguinetti EL, Buchman A et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54(9), 1224–1231 (2005).
- Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O’Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 60(7), 902–914 (2011).
- Jeppesen PB, Pertkiewicz M, Messing B et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 143(6), 1473–1481 (2012).